Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Research expenses by Quarter
Research expenses (discovery & early preclinical) — Total ($M) ($M)
Vertex Pharmaceuticals Research expenses: $207M in Q2 2026, down 1.0% from a year earlier.
Where the Q2 2026 figure comes from
“|| Total research expenses | $ 207.3 | $ 209.3 | (1)% | $ 412.3 | $ 415.4 | (1)%”
Source: Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K MD&A & Note (Segment Significant Expenses).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up research expenses
- Research — Salary and employee benefits ($M)51.3 · Q2 2026
- Research — Stock-based compensation expense ($M)21.2 · Q2 2026
- Research — Outsourced services and other direct costs ($M)71.2 · Q2 2026
- Research — Infrastructure and facilities costs ($M)63.6 · Q2 2026
- Research — Collaborative & upfront licensing payments (FY2015–FY2021, $M)51.2 · Q4 2021
- Research — Outsourced services ex-lab supplies (FY2013–FY2018, $M)10.7 · Q4 2018
- Research — Laboratory supplies (standalone through FY2018, $M)13.3 · Q4 2018
Cite this data
StockData. (2026). Vertex Pharmaceuticals Research expenses ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-res-total
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.